Oritavancin: a new avenue for resistant Gram-positive bacteria

References

• Amstead GM, Owens AD. Recent advances in the treatment of infections due to resistant Staphylococcus aureus. Curr. Opin. Infect. Dis. 17, 549–555 (2004).
   PubMedGoogle Scholar
• Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg. Infect. Dis. 7, 1–10 (2001).
   PubMedGoogle Scholar
• National Nosocomial Infections Surveillance (NNIS) System Report. Am. J. Infect. Control. 31, 481–498 (2003).
   PubMed Web of Science ®Google Scholar
• Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin. Infect. Dis. 36, 131–139 (2003).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin – United States, 1997. MMWR Morb. Mortal. Wkly Rep. 46, 765–766 (1997).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin – Illinois, 1999. MMWR Morb. Mortal. Wkly Rep. 48, 1165–1167 (2000).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin – United States, 2002. MMWR Morb. Mortal. Wkly Rep. 51, 565–567 (2002).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin – United States, 1997. MMWR Morb. Mortal. Wkly Rep. 46, 813–815 (1997).
   PubMedGoogle Scholar
• Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115, 462–474 (1999).
   PubMed Web of Science ®Google Scholar
• Irequi M, Ward S, Sherman G, Fraser VJ, Kollef, MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122, 262–268 (2002).
   PubMedGoogle Scholar
• Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207–208 (2001).
   PubMed Web of Science ®Google Scholar
• Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N. Engl. J. Med. 346(11), 867–869 (2002).
   PubMed Web of Science ®Google Scholar
• Potoski BA, Mangino JE, Goff DA. Clinical failures of linezolid and implications for the clinical microbiology laboratory. Emerg. Infect. Dis. 8(12), 1519–1520 (2002).
   PubMedGoogle Scholar
• Meka VG, Pillai SK, Sakoulas G et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J. Infect. Dis. 190, 311–317 (2004).
   PubMed Web of Science ®Google Scholar
• Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357, 1179 (2001).
   PubMed Web of Science ®Google Scholar
• Silverman JA, Oliver N, Andrew T, Li T. Resistance studies with daptomycin. Antimicrob. Agents Chemother. 45(6), 1799–1802 (2001).
   PubMed Web of Science ®Google Scholar
• Bersos Z, Maniati M, Kontos F, Petinaki E, Maniatis AN. First report of a linezolid-resistant vancomycin-resistant Enterococcus faecium strain in Greece. J. Antimicrob. Chemother. 53(4), 685–686 (2004).
   PubMedGoogle Scholar
• Sabol K, Patterson JE, Lewis JS, Owens A, Cadena J, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob. Agents Chemother. 49(4), 1664–1665 (2005).
   PubMed Web of Science ®Google Scholar
• Luh KT, Hsueh PR, Teng LJ et al. Quinupristin-dalfopristin resistance among Gram-positive bacteria in Taiwan. Antimicrob. Agents Chemother. 44(12), 3374–3380 (2000).
   PubMed Web of Science ®Google Scholar
• Malbruny B, Canu A, Bozdogan B et al. Resistance to quinupristin dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob. Agents Chemother. 46(7), 2200–2207 (2002).
   PubMedGoogle Scholar
• Bradford PA. Tigecycline: a first in class glycylcyclines. Clin. Microb. Newsletter 26(21), 163–168 (2004).
   Google Scholar
• Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol. Rev. 26, 511–532 (2003).
   PubMed Web of Science ®Google Scholar
• Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Glycopeptide antibiotics from conventional molecules to new derivatives. Drugs 64(9), 913–936 (2004).
   PubMed Web of Science ®Google Scholar
• Van Bambeke F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol. 4, 471–478 (2004).
   PubMed Web of Science ®Google Scholar
• Lin G, Credito K, Ednie LM, Appelbaum PC. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob. Agents Chemother. 49(2), 770–772 (2005).
   PubMed Web of Science ®Google Scholar
• Biavasco F, Vignaroli C, Lupidi R, Manso E, Facinelli B, Varaldo PE. In vitro antibacterial activity of LY-333328, a new semisynthetic glycopeptide. Antimicrob. Agents Chemother. 41(10), 2165–2176 (1997).
   PubMed Web of Science ®Google Scholar
• Zeckel ML, Preston DA, Allen BS. In vitro activities of LY-333328 and comparative agents against nosocomial Gram-positive pathogens collected in a 1997 global surveillance study. Antimicrob. Agents Chemother. 44(5), 1370–1374 (2000).
   PubMed Web of Science ®Google Scholar
• Garcia-Garrote F, Cercenado E, Alcala L, Bouza E. In vitro activity of the new glycopeptide LY-333328 against multiply resistant Gram-positive clinical isolates. Antimicrob. Agents Chemother. 42(9), 2452–2455 (1998).
   PubMed Web of Science ®Google Scholar
• Jones RN, Barrett MS, Erwin ME. In vitro activity and spectrum of LY-333328, a novel glycopeptide derivative. Antimicrob. Agents Chemother. 41(2), 4888–4893 (1996).
   Google Scholar
• Noviello S, Ianniello F, Esposito S. In vitro activity of LY-333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci. J. Antimicrob. Chemother. 48, 283–286 (2001).
   PubMed Web of Science ®Google Scholar
• Schwalbe RS, McIntosh AC, Qaiyumi S et al. In vitro activity of LY-333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob. Agents Chemother. 40(10), 2416–2419 (1996).
   PubMed Web of Science ®Google Scholar
• Harland S, Tebbs SE, Elliott TSJ. Evaluation of the in vitro activity of the glycopeptide antibiotic LY-333328 in comparison with vancomycin and teicoplanin. J. Antimicrob. Chemother. 41, 273–276 (1998).
   PubMed Web of Science ®Google Scholar
• Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 55, 283–288 (2005).
   PubMed Web of Science ®Google Scholar
• Fraise AP, Andrews J, Wise R. Activity of a new glycopeptide antibiotic (LY-333328) against enterococci and other resistant Gram-positive organisms. J. Antimicrob. Chemother. 40, 423–425 (1997).
   PubMedGoogle Scholar
• Aeschlimann JR, Allen GP, Hershberger E, Rybak MJ. Activities of LY-333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrob. Agents Chemother. 44(11), 2991–2998 (2000).
   PubMed Web of Science ®Google Scholar
• Paladino JA. Linezolid: an oxazolidinone antimicrobial agent. Am. J. Health Syst. Pharm. 59(15), 2413–2425 (2002).
   PubMed Web of Science ®Google Scholar
• Zurenko GE, Yagi BH, Schaadt RD et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40(4), 839–845 (1996).
   PubMed Web of Science ®Google Scholar
• Richter SS, Kealey DE, Murray CT, Heilmann KP, Coffman SL, Doern GV. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J. Antimicrob. Chemother. 52, 123–127 (2003).
   PubMed Web of Science ®Google Scholar
• Streit JM, Steenbergen JN, Thorne GM, Alder J, Jones RN. Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. J. Antimicrob. Chemother. 55, 574–578 (2005).
   PubMedGoogle Scholar
• Chant C, Rybak MJ. Quinupristin/dalfopristin (RP59500): a new streptogramin antibiotic. Ann. Pharmacother. 29, 1022–1027 (1995).
   PubMedGoogle Scholar
• Thorne GM, Alder J. Daptomycin: a novel lipopeptide antibiotic. Clin. Microb. Newsletter 24(5), 33–40 (2002).
   Google Scholar
• Mercier RC, Houlihan HH, Rybak MJ. Pharmacodynamic evaluation of a new glycopeptide, LY-333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob. Agents Chemother. 41(6), 1307–1312 (1997).
   PubMed Web of Science ®Google Scholar
• Boylan CJ, Campanale K, Iversen PW, Phillips DL, Zeckel ML, Parr TR. Pharmacodynamics of oritavancin (LY-333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 47(5), 1700–1706 (2003).
   PubMed Web of Science ®Google Scholar
• Van Bambeke F, Carryn S, Seral C et al. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY-333328) in a model of J774 mouse macrophages. Antimicrob. Agents Chemother. 48(8), 2853–2860 (2004).
   PubMed Web of Science ®Google Scholar
• Gerber J, Smirnov A, Wellmer A et al. Activity of LY-333328 in experimental meningitis caused by a Streptococcus pneumoniae strains susceptible to penicillin. Antimicrob. Agents Chemother. 45(7), 2169–2172 (2001).
   PubMed Web of Science ®Google Scholar
• Cabellos C, Fernandez A, Maiquies JM et al. Experimental study of LY-333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 47(6), 1907–1911 (2003).
   PubMed Web of Science ®Google Scholar
• Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, Mercier RC, Rybak MJ. Efficacy of LY-333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 42(4), 981–983 (1998).
   PubMed Web of Science ®Google Scholar
• Lefort A, Saleh-Mghir A, Garry L, Carbon C, Fantin B. Activity of LY-333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 44(11), 3017–3021 (2000).
   PubMed Web of Science ®Google Scholar
• Zelenitsky SA, Booker B, Laing N, Karlowsky JA, Hoban DJ, Zhanel GG. Synergy of an investigational glycopeptide, LY-333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 43(3), 592–597 (1999).
   PubMedGoogle Scholar
• Saleh-Mghir A, Lefort A, Petegnief Y et al. Activity and diffusion of LY-333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 43(1), 115–120 (1999).
   PubMed Web of Science ®Google Scholar
• Mercier RC, Stumpo C, Rybak MJ. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY-333328), against Staphylococcus aureus and Enterococcus faecium. J. Antimicrob. Chemother. 50, 19–24 (2002).
   PubMed Web of Science ®Google Scholar
• Fetterly G, Ong ChM, Bhavnani SM et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200mg dose for 3 days or a single 800mg dose. Antimicrob. Agents Chemother. 49(1), 148–152 (2005).
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn. Microbiol. Infect. Dis. 50(2), 95–102 (2004).
   PubMed Web of Science ®Google Scholar
• Wasilewski M, Disch D, McGill J et al. Equivalence of shorter course therapy with oritavancin compared to vancomycin/cephalexin in complicated skin/skin structure infections. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, September 22–25 (2001) (Poster).
   Google Scholar
• Giamarellou H, O’Riordan W, Harris H et al. Phase 3 trial comparing 3–7 days of oritavancin vs. 10–14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, September 14–17 (2003) (Poster L-739a).
   Google Scholar
• Bhavnani SM, Ballow CH. New agents for Gram-positive bacteria. Curr. Opin. Infect. Dis. 3, 526–534 (2000).
   Google Scholar